TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07384975: A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa

Sponsor: Navigator Medicines, Inc. · Phase: PHASE2 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 150 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$1,986,600

Rescue Site Savings

+$1,315,800

Unlock Full NCT07384975 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07384975 Rescue Dossier →